Top Spasticity Treatment Companies

Global Spasticity Treatment Market size was valued at USD 1.68 Billion in 2023 and is poised to grow from USD 1.54 Billion in 2024 to USD 2.44 Billion by 2032, growing at a CAGR of 8.02% in the forecast period (2025-2032).

The global spasticity treatment market is highly competitive, with prominent players focusing sharp attention on improving product portfolios and patient outcomes. Companies are investing in and developing new therapies, mainly in the form of oral medications or botulinum toxin-based treatments. Most major firms on the market go for strategic partnerships, acquisitions, and regional expansions in their efforts to position themselves in the industry. 'Allergan', 'Ipsen', 'Merz Pharmaceuticals', 'Zambon', 'Teva Pharmaceutical Industries', 'AbbVie', 'Mylan N.V.', 'UCB Pharma', 'Medtronic', 'Novartis', 'Mallinckrodt Pharmaceuticals', 'Bausch Health', 'Lundbeck', 'Amgen', 'Sanofi'

Among the most significant drivers of growth in the spasticity treatment market is the growing prevalence of neurological diseases such as cerebral palsy, multiple sclerosis, and stroke-induced spasticity. Against the backdrop of the growing incidence of these disorders across the globe, there is a growing demand for effective treatments like oral drugs, physical therapy, and botulinum toxins, which is fueling the growth of the market.

Implementation of Minimally Invasive Procedures: In the management of spasticity, there has been an increased trend towards the use of less invasive treatment methods, including intrathecal medication infusion devices and botulinum toxin injections. Particularly with the localized type of spasticity, such treatment is extremely common among doctors as it provides temporary relief but with less pain and a shorter duration of recovery. This is particularly common in this situation.

Why Is North America Leading the Global Spasticity Treatment Market?